关键字:
心脏病

    字体: | |

心源性休克与氯吡格雷(cardiogenic shock and clopidogrel)
原作者: 肖锋译 文章来源: 中华急诊医学杂志编辑部 发布日期:2013-01-18

Title: cardiogenic shock and clopidogrel
题目:心源性休克与氯吡格雷
Author 作者: Amal Mattu

Patients with ACS are often treated early with clopidogrel. However, if the patient with ACS appears to be developing cardiogenic shock, its probably best to withhold the early clopidogrel.
急性冠状综合症(ACS)的病人通常要尽快给氯吡格雷。但是,如果病人有发生心源性休克的迹象,最好不要给氯吡格雷。
The literature indicates that patients with cardiogentic shock benefit most from emergent PCI, and many of these patients will need CABG. Generally it's best to avoid clopidogrel in patients heading for CABG.


目前文献显示,对心源性休克的病人最有效的治疗方法是紧急经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI),其中很多病人可能需要冠状动脉搭桥术(coronary artery bypass graft,CABG)。一般来说,最好对这些有可能需要CABG的病人避免氯吡格雷。(因此药可增加CABG病人的出血倾向。)
The use of clopidogrel in patients with cardiogenic shock can be deferred to the cardiologists in the cath lab once they decide whether the patient will need CABG or not.
对心源性休克的病人是否使用氯吡格雷,可由导管室的心脏科医生根据病人是否需要CABG来决定。
References 参考文献

Thiele H, Allam B, Chatellier G, et al. Shock in acute myocardial infarction: the Cape Horn for trials? Eur Heart J 2010;31:1828-1835.

文章来源:中华急诊医学杂志编辑部